A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Vanutide cridificar (Primary) ; QS 21
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms ACCTION
  • Sponsors JANSSEN Alzheimer Immunotherapy
  • Most Recent Events

    • 27 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 21 Aug 2013 Pfizer reported that the development of this vaccine has been discontinued. This, and one other PET imaging trial underway in the US will continue, as they are providing biomarker data.
    • 17 Jan 2012 Planned End Date changed from 1 Aug 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top